Minerva Surgical, Inc. (NASDAQ:UTRS – Get Rating) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 219,000 shares, a decrease of 15.6% from the June 30th total of 259,500 shares. Currently, 2.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 35,700 shares, the days-to-cover ratio is presently 6.1 days.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler decreased their price objective on shares of Minerva Surgical from $12.00 to $6.00 in a research note on Thursday, May 12th.
Institutional Trading of Minerva Surgical
Hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new stake in shares of Minerva Surgical during the fourth quarter valued at approximately $451,000. Ghisallo Capital Management LLC bought a new position in Minerva Surgical in the fourth quarter valued at approximately $386,000. Vanguard Group Inc. boosted its stake in Minerva Surgical by 64.8% in the first quarter. Vanguard Group Inc. now owns 378,781 shares of the company’s stock valued at $1,705,000 after acquiring an additional 148,915 shares during the last quarter. Commonwealth Equity Services LLC bought a new position in Minerva Surgical in the second quarter valued at approximately $54,000. Finally, Novo Holdings A S bought a new position in Minerva Surgical in the fourth quarter valued at approximately $10,574,000. 69.55% of the stock is owned by institutional investors.
Minerva Surgical Price Performance
Minerva Surgical (NASDAQ:UTRS – Get Rating) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.07). The firm had revenue of $10.94 million for the quarter, compared to analyst estimates of $10.91 million. Sell-side analysts anticipate that Minerva Surgical will post -1.29 EPS for the current fiscal year.
Minerva Surgical Company Profile
Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.
- Get a free copy of the StockNews.com research report on Minerva Surgical (UTRS)
- AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.